Clinical disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change medication without clinical supervision.

Key Points

  • STEP-HFpEF focused on the obesity-related HFpEF phenotype specifically, not all heart failure
  • Semaglutide improved Kansas City Cardiomyopathy Questionnaire score, 6-minute walk distance, and body weight
  • Symptom and function gains were the point, not just scale change
  • The trial does not prove semaglutide is a universal HFpEF treatment across all phenotypes
  • HFpEF care requires integrated cardiovascular and metabolic supervision

STEP-HFpEF matters because it brought obesity medicine into a syndrome that has long frustrated both patients and cardiologists. In 529 patients with obesity-related heart failure with preserved ejection fraction, semaglutide improved Kansas City Cardiomyopathy Questionnaire clinical summary score by 16.6 points versus 8.7 with placebo, improved 6-minute walk distance by 21.5 metres versus 1.2 metres, and reduced body weight by 13.3% versus 2.6% at 52 weeks. [1,2]

Those are not cosmetic gains. They are symptom and function gains in a condition where pharmacological progress has often been disappointing.

The trial design

The trial enrolled patients with obesity-related HFpEF and compared semaglutide 2.4 mg weekly with placebo over 52 weeks. [1] Its significance lies partly in choosing outcomes that patients actually feel: symptoms, physical limitations, and functional capacity.

What most articles miss

This was not a general heart-failure trial. It focused on the obesity-related HFpEF phenotype. [1] Too many summaries obsess over body weight and miss the fact that breathlessness, fatigue, and function are the point. The trial does not prove semaglutide is a universal HFpEF treatment across every phenotype. It also does not resolve how much of the benefit is mediated by weight reduction versus broader metabolic and inflammatory pathways.

What this means in practice

STEP-HFpEF gives clinicians a stronger basis to treat obesity seriously in people whose HFpEF symptoms have too often been managed with resignation. It also supports better phenotyping. Not every patient with dyspnoea and obesity has the same driver map. But where the obesity-related HFpEF phenotype is present, the evidence is now harder to ignore.

When to involve your clinician

Always, because this sits inside integrated cardiovascular and metabolic care. Diuretics, blood pressure, exercise tolerance, and medication interactions all matter.

Bottom line

STEP-HFpEF matters because it showed semaglutide improved symptoms, function, and weight in obesity-related HFpEF. It is one of the clearest examples yet that treating obesity can change how a serious chronic syndrome feels in real life. [1,2]

FAQ

What did STEP-HFpEF show?
Semaglutide improved HF symptoms and physical limitations, increased 6-minute walk distance, and reduced body weight compared with placebo. [1,2]
Was the benefit only on weight?
No. Patient-reported symptoms and functional measures improved as well. [1]
Who was in STEP-HFpEF?
Patients with obesity-related heart failure with preserved ejection fraction. [1]
Does STEP-HFpEF apply to all heart failure?
No. The evidence is specific to an obesity-related HFpEF phenotype.
Why is STEP-HFpEF important?
Because it showed that obesity treatment can improve how patients with HFpEF actually feel and function. [1]

References

  1. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023. nejm.org
  2. American College of Cardiology. STEP-HFpEF Trial Summary. 2024.
  3. Wegovy (semaglutide) prescribing information. FDA. 2025.